ArticleHeliyon2024
Prognostic signature and immune landscape of 5-methylcytosine-related long non-coding RNAs in gastric cancer.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- F2R and MXRA5: the metabolic obesity-derived biomarkers for immunosuppression and poor survival in triple-negative breast cancer.Discover oncology · 2026Article
- Knockdown of 5-methylcytosine RNA methyltransferase NOP2/sun RNA methyltransferase 5 in hepatocellular carcinoma cells affects their biological functions.World journal of gastrointestinal surgery · 2026Article
- Advances in research on RNA methylation and its role in the immune microenvironment of gastrointestinal tumors.Frontiers in cell and developmental biology · 2026Review
- Competing Endogenous RNA Networks Reveal Long Non-coding RNAs as Potential Prognostic Biomarkers in Gastric Cancer: A Systematic Review and Meta-Analysis.Advanced biomedical research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Long non-coding RNAs (lncRNAs) have been demonstrated to be useful in assessing the prognosis of cancer patients. However, few studies have focused on 5-methylcytosine-related lncRNAs (m5C-lncRNAs) in gastric cancer (GC). In this study, we aimed to establish a m5C-lncRNAs prognostic signature (m5C-LPS) and explore its potential impact on guiding clinical practice for GC. Methods: RNA-sequence and clinicopathological data were retrieved from The Cancer Genome Atlas (TCGA) database, while the coexpression of long non-coding RNAs (lncRNAs) was determined using Pearson's correlation analysis. A m5C-LPS model was constructed using univariate and Lasso Cox regression, and its prognostic value and accuracy were subsequently validated. Subsequently, the expression of 11 m5C-lncRNAs was verified via quantitative real-time PCR (qRT-PCR) in gastric cancer (GC) cell lines. The potential biological mechanism of this signature was elucidated using Gene Set Enrichment Analysis (GSEA). Based on the GSEA findings, CIBERSORT and ESTIMATE algorithms were utilized to conduct a comprehensive investigation of the tumor immune microenvironment (TIME) in GC. Additionally, pRRophetic and TIDE algorithms were employed to predict drug sensitivity and the efficacy of immunotherapy for GC patients. Results: 280 lncRNAs were identified as m5C-lncRNAs, including RHPN1-AS1, AC093752.3, TSC22D1-AS1, AL391152.1, MAGI2-AS3, AC048382.2, AL033527.3, AC007405.2, AC036103.1, CCDC183-AS1, and ADORA2A-AS1. Their prognostic value was validated, and the expression of these 11 lncRNAs was confirmed in four gastric cancer cell lines using quantitative reverse transcription PCR (qRT-PCR). A nomogram incorporating a risk score was developed to provide more precise clinical decision-making. Gene Set Enrichment Analysis (GSEA) showed that many classical signaling pathways related to tumor progression were enriched in this signature. Analyses related to immunity and drug sensitivity demonstrated distinct differences in features between high-risk and low-risk subgroups. Conclusion: The m5C-LPS can predict the survival of gastric cancer (GC) patients, provide novel therapeutic targets, and thus offer more thoughtful perspectives for future clinical decisions regarding GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.